Philip Morris International Inc. 2026 Third-Quarter Results - PHILIP MORRIS INTERNATIONAL INC

Financial Performance:

• Q3 2026 Net Revenues: $11.4 billion (+7.1% organic, +5.5% USD-driven).
• Q3 Adjusted Operating Income (OI): Exceeded $5 billion (+10.5% organic, +9.6% USD).
• Q3 Adjusted Operating Margin: ~45% (+130 bps organic).
• Q3 Adjusted Diluted EPS: $2.36 (+6% ex-currency, +5.4% reported).
• Year-to-Date Net Revenues: ~$33 billion (+5.9% organic).
• Year-to-Date Adjusted OI: >$14 billion (+10.6% USD).
• Year-to-Date Adjusted Diluted EPS: $6.52 (+8.4% ex-currency, +11.8% USD).
• Gross Profit Growth: +8% organically (Q3); +7.1% organically (YTD).
• Cash Flow: Expected to generate record operating cash flow of ~$13.5 billion for the full year.
• SG&A: Increased significantly in Q3 ($370M) to support US investments; expected to rise further in Q4 but run in line with revenues for the full year.

Guidance and Future Outlook:

• Full Year 2026 Total Shipments: Expected to grow (+0.6% in Q3), marking the sixth consecutive year of volume growth.
• Full Year Organic Net Revenue: Forecast +5% to +7%; likely landing in the middle or upper half due to strong Q4 expectations.
• Full Year Organic OI Growth: Forecast +7% to +9%.
• Full Year Currency-Neutral Adjusted EPS Growth: Forecast +7.5% to +9.5%.
• Full Year Reported Adjusted EPS: Forecast $8.29 to $8.44 (approx. +10% to +12% growth), with actual delivery likely at the midpoint or lower half due to US investment headwinds and geopolitical costs.
• Q4 US Outlook: Exceptional investment quarter; adjusted OI expected to be near zero or slightly negative due to portfolio transition and marketing spend.
• 2027 Outlook: Confidence in sustained double-digit EPS growth, strong pricing power, and continued smoke-free momentum.
• Dividend: Raised for the 19th consecutive year to $6.40 per share (+9%).

Business Segments and Product Lines:

• ICO (iQOS): Adjusted IMS volume growth of +7.1% in Q3 (+10% ex-Japan/Poland); HTU shipments 41.5 billion units in Q3. Strong growth in Germany, Spain, Greece, Indonesia, and global travel retail.
• Veev (e-Vapor): Shipment growth of +62% in Q3 (+68% YTD). Expanded market leadership in Europe; launched new "Veev OnePlus" device.
• Zyn (Nicotine Pouches): US shipment growth of +4.2% in Q3 (+13% ex-promotional base); International growth +6.3% (like-for-like).
• US Zyn Initiatives: Rolled out "Wave 1" expansion (Ultra moist range, new flavors) and "Wave 2" (1.5mg and 8mg variants). Transitioning flagship variants from 15 to 20 pouches (effective Q4) to improve value proposition, causing a ~25% revenue reduction per pouch but expected to boost volume long-term.
• Combustibles: Q3 pricing +8.9%; International category share increased 0.4 points to 25.9%, driven by Marlboro record share (11.4%).
• Japan: HTU IMS growth +3.4% in Q3 following April excise increase; expected to face softer Q4 due to inventory drawdown after October price increase.

Market and Competitive Landscape:

• Smoke-Free Mix: Smoke-free shipments +2.7% in Q3, offsetting combustible declines; international smoke-free IMS growth +8.6% YTD, outgrowing industry by ~1%.
• Market Share: International smoke-free market share at 62%; combined cigarettes and HDU share exceeded 30% globally.
• Competitive Position: Veev is #1 closed pod brand in Europe; Zyn gained 1.4 points of US category take-share between June and September.
• Geographic Trends: Strong double-digit growth in new markets (Mexico, Indonesia, Taiwan) where ICOS shares exceed 80%; regulatory opening in Argentina anticipated.
• Industry Context: PMI shipments +0.6% vs. industry decline of 1.1% (combustibles).

Risks and Challenges:

• Geopolitical Tensions: Conflicts in Ukraine and the Middle East impacting costs and supply chains; estimated to drag full-year EPS growth by ~1% combined.
• Inflationary Pressures: Energy and input costs rising due to Middle East conflict; expected to impact Q4 more than Q3; estimated full-year EPS drag of 0.5%.
• Regulatory/Tax Headwinds: Excise hikes in Japan (April/October) and Poland (flavor ban) causing temporary volume and revenue headwinds.
• US Revenue Impact: Transition to 20-pouch cans and increased marketing spend will suppress Q4 US revenue and profitability.
• Japan Price Sensitivity: Higher excise taxes in Japan creating consumer adjustment risks, though long-term growth potential remains.

Management Commentary and Tone:

• Tone: Confident and positive regarding long-term fundamentals, describing performance as "best-in-class" despite headwinds.
• Strategic Focus: Emphasized the dual engine of smoke-free innovation (ICOS, Veev, Zyn) and combustible resilience.
• US Strategy: Acknowledged the "unique" Q4 nature of US investment but framed it as necessary for mid- and long-term Zyn dominance.
• Supply Chain Resilience: Highlighted ability to absorb inflation better than FMCG peers due to diversified sourcing and hedging contracts.
• Cost Discipline: Achieved $2B+ in cumulative cost savings ahead of schedule; SG&A productivity initiatives ongoing.

Analyst Questions and Answers:

• Guidance & Costs (Bonnie Herzog, Goldman Sachs): Confirmed full-year OI and EPS likely to land mid-to-lower end of ranges due to geopolitical inflation (+1% impact) and exceptional US investments; clarified that US spend levels in Q3 (~$370M) are a proxy for next year's run rate.
• Zyn Innovation & Packaging (Bonnie Herzog): Noted overwhelmingly positive consumer feedback on new Ultra/Flavor variants; anticipated volume increase as consumers move from 15 to 20-pouch cans (higher pocket quantity drives consumption).
• Inflation & Margins (Matt Smith, Stiefel): Q4 expected to feel most inflationary pressure; affirmed strong pricing power and resilience; confirmed inventory levels are healthy and IMS will slightly trail shipments due to Japan phasing.
• International ICOS Outlook (Eric Sirota, Morgan Stanley): Expects 2027 growth to be supported by wider geographic diversification (double-digit growth in more markets) and new products (Bonds/Blends) targeting entrenched smokers; optimistic about Argentina market entry.
• US EBIT Trajectory (Pallav Mittal, Barclays): Did not provide 2027 EBIT guidance but noted that volume growth and cost absorption improvements in 2027 should offset the Q4 Q3 investment levels.
• Germany Taxes & Zyn Data (Andre Anden, Jefferies): Confirmed Marlboro's strong position in Germany allows competitiveness despite sharp tax increases; explained US Zyn growth (4.2%) vs. scanner data by removing September promo comparisons and accounting for new variant distribution.

Other Key Points:

• Product Portfolio: Continued rollout of new variants for Zyn (Ultra, flavors) and Veev (OnePlus device) to broaden consumer appeal.
• Inventory Management: Japan inventory dynamics (pantry loading) drove Q3 shipment vs. IMS divergence; expected to normalize in Q4.
• Global Travel Retail: Identified as a key growth driver for ICOS across multiple regions.
• Shareholder Returns: Commitment to deleveraging and attractive returns alongside dividend growth.